Comparative Pharmacology
Head-to-head clinical analysis: FORTAZ versus VELOSEF 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAZ versus VELOSEF 500.
FORTAZ vs VELOSEF '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
Cephradine inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis and death. It is a first-generation cephalosporin with bactericidal activity.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
500 mg orally every 6 hours for 10 days.
None Documented
None Documented
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Terminal elimination half-life: 1.2 hours in adults with normal renal function; prolonged to 8-15 hours in severe renal impairment (CrCl <10 mL/min); clinical context: dosing interval adjustment required for renal impairment
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Renal excretion of unchanged drug: >90% (glomerular filtration and tubular secretion); biliary/fecal: <1%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic